Compare Aptiv PLC (APTV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Summit Therapeutics Inc — how do they compare? Aptiv PLC trades at $49.62 (market cap $10.30B), while Summit Therapeutics Inc trades at $15.19 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| APTV | SMMT | |
|---|---|---|
Market Cap | $10.30B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $26.98 |
52-Week Low | $46.30 | $12.55 |
Enterprise Value | $15.23B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $49.81, up 0.52% on the day, but remains under pressure following a lowered 2026 outlook despite recent earnings beats. Technical indicators are bearish, with the stock near support at $49. Fundamentally, revenue grew to $20.40B in 2025, but net income margin compressed to 1.07%, reflecting margin pressure. The company faces headwinds from China demand weakness and program delays, as highlighted in recent news.
The investment case balances a low valuation (P/E 22.45, P/S 0.52) and strong analyst buy ratings (63.64% buy) against near-term execution risks and cash flow volatility. Upside to the $70.09 consensus target exists if operational improvements materialize, but investors must weigh guidance cuts and competitive threats in the auto sector.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
